JP5734654B2 - Ｃ型肝炎を治療するためのウラシルまたはチミン誘導体 - Google Patents

Ｃ型肝炎を治療するためのウラシルまたはチミン誘導体 Download PDF

Info

Publication number
JP5734654B2
JP5734654B2 JP2010525102A JP2010525102A JP5734654B2 JP 5734654 B2 JP5734654 B2 JP 5734654B2 JP 2010525102 A JP2010525102 A JP 2010525102A JP 2010525102 A JP2010525102 A JP 2010525102A JP 5734654 B2 JP5734654 B2 JP 5734654B2
Authority
JP
Japan
Prior art keywords
tert
butyl
dioxotetrahydropyrimidin
group
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010525102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010539186A5 (enExample
JP2010539186A (ja
Inventor
ワグナー，ロルフ
テユフアノ，マイケル・デイー
スチユワート，ケント・デイー
ロツクウエイ，トツド・ダブリユ
ランドルフ，ジヨン・テイー
プラツト，ジヨン・ケイ
モツター，クリストフアー・イー
マーリング，クラレンス・ジエイ
ロングネツカー，ケントン・エル
リウ，ヤーヤー
リウ，ターチユン
クリユーガー，アラン・シー
ケイテイ，ウオーレン・エム
ハツチンソン，ダグラス・ケイ
ホワン，ペギー・ピー
フレンテ，チヤールズ・エイ
ドナー，パメラ・エル
デイゴーイ，デイビツド・エイ
ベテベナー，デイビツド・エイ
バーンズ，デイビツド・エム
チエン，シヨワン
フランチエク・セカンド，サデイアス・エス
ガオ，イー
へイト，アンソニー・アール
ヘンジベルド，ジヨン・イー
ヘンリー，ロジヤー・エフ
コテツキー，ブライアン・ジエイ
ロウ，シヤオチユン
サリス，キヤシー
ジヤン，ジエフ・ジー・ゼツト
Original Assignee
アッヴィ・バハマズ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39948002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5734654(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アッヴィ・バハマズ・リミテッド filed Critical アッヴィ・バハマズ・リミテッド
Publication of JP2010539186A publication Critical patent/JP2010539186A/ja
Publication of JP2010539186A5 publication Critical patent/JP2010539186A5/ja
Application granted granted Critical
Publication of JP5734654B2 publication Critical patent/JP5734654B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2010525102A 2007-09-17 2008-09-17 Ｃ型肝炎を治療するためのウラシルまたはチミン誘導体 Expired - Fee Related JP5734654B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97287707P 2007-09-17 2007-09-17
US60/972,877 2007-09-17
US9679108P 2008-09-13 2008-09-13
US61/096,791 2008-09-13
PCT/US2008/076576 WO2009039127A1 (en) 2007-09-17 2008-09-17 Uracil or thymine derivative for treating hepatitis c

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012225875A Division JP2013049681A (ja) 2007-09-17 2012-10-11 Ｃ型肝炎を治療するためのウラシルまたはチミン誘導体

Publications (3)

Publication Number Publication Date
JP2010539186A JP2010539186A (ja) 2010-12-16
JP2010539186A5 JP2010539186A5 (enExample) 2012-11-15
JP5734654B2 true JP5734654B2 (ja) 2015-06-17

Family

ID=39948002

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010525102A Expired - Fee Related JP5734654B2 (ja) 2007-09-17 2008-09-17 Ｃ型肝炎を治療するためのウラシルまたはチミン誘導体
JP2012225875A Pending JP2013049681A (ja) 2007-09-17 2012-10-11 Ｃ型肝炎を治療するためのウラシルまたはチミン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012225875A Pending JP2013049681A (ja) 2007-09-17 2012-10-11 Ｃ型肝炎を治療するためのウラシルまたはチミン誘導体

Country Status (30)

Country Link
US (3) US8415351B2 (enExample)
EP (2) EP2222646B1 (enExample)
JP (2) JP5734654B2 (enExample)
KR (2) KR101660360B1 (enExample)
CN (2) CN102746239B (enExample)
AR (2) AR070027A1 (enExample)
AU (1) AU2008302448B2 (enExample)
BR (1) BRPI0816994B8 (enExample)
CA (2) CA2699981C (enExample)
CL (2) CL2008002794A1 (enExample)
CO (1) CO6260076A2 (enExample)
CR (2) CR11316A (enExample)
DO (2) DOP2010000084A (enExample)
ES (1) ES2453591T3 (enExample)
GT (1) GT201000061A (enExample)
IL (1) IL204547A (enExample)
IN (1) IN2012DN05113A (enExample)
MX (2) MX2010002905A (enExample)
MY (1) MY162760A (enExample)
NZ (3) NZ600371A (enExample)
PA (1) PA8796201A1 (enExample)
PE (2) PE20130209A1 (enExample)
PH (1) PH12013500365A1 (enExample)
RU (2) RU2543620C2 (enExample)
SG (1) SG183733A1 (enExample)
TW (2) TWI534137B (enExample)
UA (1) UA117800C2 (enExample)
UY (1) UY31344A1 (enExample)
WO (1) WO2009039127A1 (enExample)
ZA (2) ZA201204224B (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010002904A (es) 2007-09-17 2010-06-02 Abbott Lab N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv).
AU2008302448B2 (en) 2007-09-17 2014-11-06 Abbvie Ireland Unlimited Company Uracil or thymine derivative for treating hepatitis C
PL2639226T3 (pl) 2007-09-17 2017-02-28 Abbvie Bahamas Ltd. Pirymidyny o działaniu przeciw zakaźnym oraz ich zastosowania
CA2705586A1 (en) * 2007-11-16 2009-05-22 Schering Corporation 3-heterocyclic substituted indole derivatives and methods of use thereof
KR20110033291A (ko) 2008-07-23 2011-03-30 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물
CA2736472A1 (en) 2008-09-26 2010-04-01 F. Hoffmann-La Roche Ag Pyrine or pyrazine derivatives for treating hcv
CA2753825C (en) * 2009-03-24 2017-10-17 Abbott Laboratories Process for preparing substituted pyrimidine antiviral compound
CN102448952B (zh) * 2009-03-25 2014-10-29 Abbvie公司 抗病毒化合物和其用途
US20120065247A1 (en) * 2009-03-27 2012-03-15 Discoverybiomed, Inc. Modulating ires-mediated translation
SG175774A1 (en) 2009-04-25 2011-12-29 Hoffmann La Roche Heterocyclic antiviral compounds
TWI428332B (zh) 2009-06-09 2014-03-01 Hoffmann La Roche 雜環抗病毒化合物
EP2445875A2 (en) * 2009-06-24 2012-05-02 F. Hoffmann-La Roche AG Heterocyclic antiviral compound
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
WO2011033045A1 (en) 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
KR20120085918A (ko) * 2009-11-21 2012-08-01 에프. 호프만-라 로슈 아게 헤테로환형 항바이러스성 화합물
WO2011073114A1 (en) 2009-12-14 2011-06-23 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
US9216952B2 (en) 2010-03-23 2015-12-22 Abbvie Inc. Process for preparing antiviral compound
CN102971305B (zh) 2010-07-07 2016-02-03 弗·哈夫曼-拉罗切有限公司 抗病毒的杂环化合物
CN105622525B (zh) 2010-07-16 2019-02-15 艾伯维巴哈马有限公司 用于制备抗病毒化合物的方法
EA030228B1 (ru) 2010-07-16 2018-07-31 ЭббВи Айэленд Анлимитед Компани Фосфиновые лиганды для каталитических реакций
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
AU2015201698B2 (en) * 2010-07-16 2017-02-02 Abbvie Ireland Unlimited Company Process for preparing antiviral compounds
RU2436786C1 (ru) * 2010-07-23 2011-12-20 Александр Васильевич Иващенко Замещенные индолы, противовирусный активный компонент, способ получения и применения
WO2012020725A1 (ja) * 2010-08-10 2012-02-16 塩野義製薬株式会社 Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体
CA2806547A1 (en) 2010-08-13 2012-02-16 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
CN102675092B (zh) * 2011-03-14 2014-11-05 江苏中丹药物研究有限公司 一种制备2-芳基-2,2-二甲基乙酸甲酯的方法
TWI558400B (zh) 2011-03-18 2016-11-21 艾伯維有限公司 苯基尿嘧啶化合物之調配物
JP2014510743A (ja) * 2011-03-31 2014-05-01 シェファー、コンスタンツェ 核酸の非ウイルスの導入のためのパーフルオロ化化合物
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
JP5734124B2 (ja) * 2011-07-21 2015-06-10 株式会社 東邦アーステック １，３−ジヨードヒダントイン類の製造方法
EP2740728A4 (en) 2011-08-01 2015-04-01 Sumitomo Dainippon Pharma Co Ltd URACIL DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES
DE112012003457T5 (de) 2011-10-21 2015-03-12 Abbvie Inc. Kombinationsbehandlung (z.B. mit ABT-072 oder ABT-333 von DAAs zur Verwendung in der Behandlung von HCV)
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
TWI532487B (zh) 2011-10-21 2016-05-11 艾伯維有限公司 治療ｃ型肝炎病毒（ｈｃｖ）之方法
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AU2015200715A1 (en) * 2011-10-21 2015-03-05 Abbvie Ireland Unlimited Company Methods for treating HCV
EP2861579B9 (en) 2012-05-15 2018-08-29 Novartis AG Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
US9315489B2 (en) 2012-05-15 2016-04-19 Novartis Ag Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
CN104379574B (zh) 2012-05-15 2017-03-01 诺华股份有限公司 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物
US9340537B2 (en) 2012-05-15 2016-05-17 Novatis Ag Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
JP2015522022A (ja) 2012-06-27 2015-08-03 アッヴィ・インコーポレイテッド Ｈｃｖの処置に使用するためのａｂｔ−４５０およびリトナビルおよび例えばａｂｔ−０７２および／またはａｂｔ−３３３の併用処置
CA2882624A1 (en) * 2012-08-21 2014-02-27 Shashank Shekhar Process for preparing antiviral compounds
US9629841B2 (en) * 2012-10-18 2017-04-25 Abbvie Inc. Formulations of pyrimidinedione derivative compounds
JP2014101316A (ja) * 2012-11-20 2014-06-05 Toyobo Co Ltd ベンゾ［１，２−ｄ；４，５−ｄ’］ビスチアゾール化合物の製造方法
JP2016523924A (ja) 2013-07-02 2016-08-12 アッヴィ・インコーポレイテッド Ｈｃｖの治療方法
CN105517995B (zh) 2013-07-08 2018-10-02 拜耳作物科学股份公司 作为农药的六元c-n键合的芳基硫化物和芳基硫氧化物衍生物
DK3043803T3 (da) 2013-09-11 2022-08-01 Univ Emory Nukleotid- og nucleosidsammensætninger og deres anvendelse
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
US20150209403A1 (en) 2014-01-28 2015-07-30 Abbvie Inc. Dose Adjustment
SI3102576T1 (sl) 2014-02-03 2019-08-30 Vitae Pharmaceuticals, Llc Inhibitorji dihidropirolopiridina ROR-gama
CN106065009B (zh) * 2014-06-28 2019-03-01 广东东阳光药业有限公司 作为丙型肝炎抑制剂的化合物及其在药物中的应用
WO2016004513A1 (en) * 2014-07-11 2016-01-14 Simon Fraser University Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods
MX378273B (es) 2014-08-01 2025-03-10 Nuevolution As Compuestos activos hacia bromodominios.
WO2016040588A1 (en) 2014-09-11 2016-03-17 Abbvie Inc. Treatment of hcv by administering four different anti-hcv compounds with food
ES2715458T7 (es) 2014-10-14 2020-05-28 Vitae Pharmaceuticals Llc Inhibidores de dihidropirrolopiridina de ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
RU2590952C1 (ru) * 2015-05-26 2016-07-10 Вячеслав Энгельсович Семёнов Средство гепатопротекторного действия
WO2016196280A1 (en) 2015-06-02 2016-12-08 E I Du Pont De Nemours And Company Heterocycle-substituted bicyclic pesticides
CN108137514A (zh) * 2015-07-30 2018-06-08 百时美施贵宝公司 芳基取代的二环杂芳基化合物
EP3331876B1 (en) 2015-08-05 2020-10-07 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
BR112018010018A2 (pt) 2015-11-20 2018-11-21 Vitae Pharmaceuticals Inc moduladores de ror-gama
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
CN109689063A (zh) 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
BR112020001246A2 (pt) 2017-07-24 2020-07-21 Vitae Pharmaceuticals, Llc inibidores de rory
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CN107266373A (zh) * 2017-08-01 2017-10-20 安徽拜善晟制药有限公司 一种原料药达沙布韦的制备方法
JP7252973B2 (ja) 2018-03-26 2023-04-05 ノバルティス アーゲー Ｎ－（３－（７Ｈ－ピロロ［２，３－ｄ］ピリミジン－４－イル）フェニル）ベンズアミド誘導体
CN110483496B (zh) * 2019-07-17 2021-05-04 杭州市西溪医院 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用
JP7785663B2 (ja) * 2019-09-16 2025-12-15 ノバルティス アーゲー 二機能性分解誘導薬及びそれらの使用方法
EP3819006A1 (en) 2019-11-05 2021-05-12 Technische Universität Dresden Compounds with thymine skeleton for use in medicine
CN111518036A (zh) * 2020-04-29 2020-08-11 杭州勇诚睿生物科技有限公司 一种达沙布韦关键中间体的制备方法
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239888A (en) * 1974-11-04 1980-12-16 Pfizer Inc. 1-Phenyluracils
JPS60243017A (ja) 1984-05-16 1985-12-03 Kyowa Hakko Kogyo Co Ltd 抗けいれん組成物
US5084084A (en) 1989-07-14 1992-01-28 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
AU627906B2 (en) 1989-07-14 1992-09-03 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
ATE169915T1 (de) 1990-02-15 1998-09-15 Takeda Chemical Industries Ltd Pyrimidindionderivate, deren herstellung und verwendung
NL9001075A (enExample) 1990-05-04 1991-12-02 Duphar Int Res
EP0489480A1 (en) * 1990-12-05 1992-06-10 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
JPH05213755A (ja) 1992-02-07 1993-08-24 Nikko Kyodo Co Ltd 肝臓障害治療薬
DE19528305A1 (de) 1995-08-02 1997-02-06 Bayer Ag Substituierte Phenyluracile
US6380387B1 (en) 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
BR0016195A (pt) 1999-12-06 2002-08-13 Hoffmann La Roche 4-pirimidinil-n-acil-l-fenilalaninas
RU2264395C2 (ru) * 2000-02-04 2005-11-20 Сумитомо Кемикал Компани, Лимитед Производные урацила, гербицидная композиция, способ борьбы с сорняками и промежуточные продукты (варианты)
IL167956A (en) 2000-02-04 2009-02-11 Sumitomo Chemical Co Isocyanate compounds
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR100589964B1 (ko) * 2003-06-13 2006-06-19 주식회사 엘지생명과학 Ｃ형 간염 바이러스의 억제제
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
PE20080209A1 (es) * 2006-06-23 2008-05-15 Smithkline Beecham Corp Derivados de glicina como inhibidores de prolil hidroxilasa
PL2639226T3 (pl) * 2007-09-17 2017-02-28 Abbvie Bahamas Ltd. Pirymidyny o działaniu przeciw zakaźnym oraz ich zastosowania
MX2010002904A (es) 2007-09-17 2010-06-02 Abbott Lab N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv).
AU2008302448B2 (en) * 2007-09-17 2014-11-06 Abbvie Ireland Unlimited Company Uracil or thymine derivative for treating hepatitis C
KR20110033291A (ko) 2008-07-23 2011-03-30 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물

Also Published As

Publication number Publication date
MX2010002905A (es) 2010-07-05
ZA201204223B (en) 2015-12-23
PH12013500365A1 (en) 2014-09-08
RU2010114828A (ru) 2011-10-27
CN102746239A (zh) 2012-10-24
US20110070193A1 (en) 2011-03-24
PA8796201A1 (es) 2009-04-23
CL2013000372A1 (es) 2013-10-04
NZ584720A (en) 2012-07-27
TWI534137B (zh) 2016-05-21
JP2013049681A (ja) 2013-03-14
CR11316A (es) 2010-10-05
EP2725015A1 (en) 2014-04-30
AU2008302448B2 (en) 2014-11-06
CN101801935B (zh) 2014-12-03
TW201443027A (zh) 2014-11-16
ES2453591T3 (es) 2014-04-08
CL2008002794A1 (es) 2009-09-04
EP2222646B1 (en) 2014-01-22
CN102746239B (zh) 2016-02-10
AR070027A1 (es) 2010-03-10
BRPI0816994B1 (pt) 2019-12-24
US9095590B2 (en) 2015-08-04
CA2699981A1 (en) 2009-03-26
KR20100068289A (ko) 2010-06-22
CO6260076A2 (es) 2011-03-22
IL204547A0 (en) 2010-11-30
BRPI0816994B8 (pt) 2021-05-25
IN2012DN05113A (enExample) 2015-10-23
UY31344A1 (es) 2009-04-30
NZ600371A (en) 2014-07-25
CA2699981C (en) 2017-08-22
GT201000061A (es) 2012-03-26
BRPI0816994A2 (pt) 2015-03-24
KR101552474B1 (ko) 2015-09-11
MX338555B (es) 2016-04-20
PE20090705A1 (es) 2009-07-17
CR20150238A (es) 2015-07-01
TWI437994B (zh) 2014-05-21
US8685991B2 (en) 2014-04-01
NZ618277A (en) 2015-07-31
KR101660360B1 (ko) 2016-09-27
US20140235638A1 (en) 2014-08-21
TW200918066A (en) 2009-05-01
KR20150117632A (ko) 2015-10-20
UA117800C2 (uk) 2018-10-10
AU2008302448A1 (en) 2009-03-26
US8415351B2 (en) 2013-04-09
SG183733A1 (en) 2012-09-27
CA2976793A1 (en) 2009-03-26
WO2009039127A1 (en) 2009-03-26
MY162760A (en) 2017-07-14
CN101801935A (zh) 2010-08-11
JP2010539186A (ja) 2010-12-16
RU2543620C2 (ru) 2015-03-10
ZA201204224B (en) 2015-12-23
DOP2010000396A (es) 2013-12-31
US20120213733A1 (en) 2012-08-23
AR087472A2 (es) 2014-03-26
EP2222646A1 (en) 2010-09-01
IL204547A (en) 2016-04-21
PE20130209A1 (es) 2013-03-24
RU2599635C2 (ru) 2016-10-10
RU2013104270A (ru) 2014-08-10
HK1147256A1 (en) 2011-08-05
DOP2010000084A (es) 2010-06-15

Similar Documents

Publication Publication Date Title
JP5734654B2 (ja) Ｃ型肝炎を治療するためのウラシルまたはチミン誘導体
JP5734655B2 (ja) 抗感染症ピリミジンおよびその使用
JP5726527B2 (ja) Ｃ型肝炎ウイルス（ｈｃｖ）阻害薬として有用なｎ−フェニル−ジオキソ−ヒドロピリミジン
AU2014280939B2 (en) Uracil or thymine derivative for treating hepatitis C
HK1189590B (en) Anti-infective pyrimidines and uses thereof
HK1156033B (en) Anti-infective pyrimidines and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120912

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130723

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20131002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131017

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140325

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140623

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140925

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150317

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150415

R150 Certificate of patent or registration of utility model

Ref document number: 5734654

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees